drugset / Trial / NCT00562809

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

NCT00562809

Phase 4 Completed 1005 enrolled Sanofi Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.

Timeline

Start
2003-07
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule 150 mg Oral
Subject Irbesartan Small molecule 300 mg Oral

Indications